Published in Science on September 08, 2006
Pathways of antigen processing. Annu Rev Immunol (2013) 2.82
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood (2010) 1.88
Finding one's way in proteomics: a protein species nomenclature. Chem Cent J (2009) 1.75
Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.58
The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci (2011) 1.35
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res (2008) 1.20
Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun (2013) 1.19
Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science (2016) 1.17
Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine (2009) 1.15
Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol (2011) 1.14
Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J Exp Med (2008) 1.14
The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics (2013) 1.13
An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc Natl Acad Sci U S A (2011) 1.03
Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol (2008) 1.01
A uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications. PLoS One (2006) 0.98
The 20S proteasome splicing activity discovered by SpliceMet. PLoS Comput Biol (2010) 0.96
Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Proc Natl Acad Sci U S A (2008) 0.94
Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine. Vaccine (2011) 0.91
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res (2010) 0.91
Concurrent detection of circulating minor histocompatibility antigen-specific CD8+ T cells in SCT recipients by combinatorial encoding MHC multimers. PLoS One (2011) 0.90
Driving forces of proteasome-catalyzed peptide splicing in yeast and humans. Mol Cell Proteomics (2012) 0.89
Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol (2009) 0.88
Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum. J Immunol (2014) 0.87
New lane in the information highway: alternative reading frame peptides elicit T cells with potent antiretrovirus activity. J Exp Med (2007) 0.86
Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy. Am J Reprod Immunol (2013) 0.84
Graft-versus-host disease: a surge of developments. PLoS Med (2007) 0.84
A peptide's perspective on antigen presentation to the immune system. Nat Chem Biol (2013) 0.84
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets. Front Immunol (2016) 0.82
Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. Infect Immun (2013) 0.82
Human Tumor Antigens and Cancer Immunotherapy. Biomed Res Int (2015) 0.81
Towards a liquid self: how time, geography, and life experiences reshape the biological identity. Front Immunol (2014) 0.80
An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J Autoimmun (2016) 0.80
Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives. Bone Marrow Transplant (2015) 0.79
Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules (2014) 0.79
Cell biology. Peptides, scrambled and stitched. Science (2006) 0.79
Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules. J Immunol (2015) 0.78
Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage. J Immunol (2015) 0.77
Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol (2012) 0.77
Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. Expert Opin Biol Ther (2011) 0.77
Computational prediction of cleavage using proteasomal in vitro digestion and MHC I ligand data. J Zhejiang Univ Sci B (2013) 0.76
Occurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling Donors. Bone Marrow Res (2012) 0.76
Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes. Sci Rep (2016) 0.76
Activation of an Endoribonuclease by Non-intein Protein Splicing. J Biol Chem (2016) 0.75
Tools to define the melanoma-associated immunopeptidome. Immunology (2017) 0.75
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol (2005) 11.48
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med (2003) 7.86
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature (2007) 7.04
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 7.01
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood (2009) 7.00
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood (2009) 3.05
Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med (2010) 3.01
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol (2009) 2.71
Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer (2004) 2.65
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity (2009) 2.64
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 2.63
Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood (2010) 2.61
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood (2002) 2.48
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood (2010) 2.45
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood (2013) 2.22
An antigenic peptide produced by peptide splicing in the proteasome. Science (2004) 2.20
Redox regulation facilitates optimal peptide selection by MHC class I during antigen processing. Cell (2006) 2.20
Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev (2002) 2.18
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood (2011) 2.15
Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood (2009) 2.00
Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res (2012) 1.98
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood (2003) 1.93
CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med (2004) 1.92
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood (2010) 1.88
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res (2007) 1.84
DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med (2011) 1.81
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest (2002) 1.79
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest (2016) 1.75
HapMap scanning of novel human minor histocompatibility antigens. Blood (2008) 1.75
Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med (2005) 1.75
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res (2009) 1.74
Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci U S A (2010) 1.70
Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther (2007) 1.70
Management of inflammatory bowel disease in pregnancy. J Crohns Colitis (2012) 1.69
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.65
Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood (2003) 1.61
A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med (2003) 1.61
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Immunol (2007) 1.56
High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med (2005) 1.55
Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med (2003) 1.55
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood (2011) 1.54
A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res (2002) 1.51
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity (2008) 1.48
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother (2012) 1.47
Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nat Immunol (2011) 1.46
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer (2012) 1.45
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res (2004) 1.42
Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood (2004) 1.42
Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res (2012) 1.41
Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res (2009) 1.37
Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol (2009) 1.36
Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J Immunol (2006) 1.36
Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A (2005) 1.36
Functional characterization of Mia40p, the central component of the disulfide relay system of the mitochondrial intermembrane space. J Biol Chem (2007) 1.35
Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 1.35
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol (2013) 1.32
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
The determinants of tumour immunogenicity. Nat Rev Cancer (2012) 1.28
Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Cell Rep (2013) 1.24
Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. Blood (2002) 1.24
Comparison of stable human Treg and Th clones by transcriptional profiling. Eur J Immunol (2009) 1.23
Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther (2009) 1.23
Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2010) 1.22
Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol (2003) 1.21
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res (2008) 1.20
HLA engineering of human pluripotent stem cells. Mol Ther (2013) 1.19
Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med (2009) 1.19
Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun (2013) 1.19
Enhanced transgene expression in quiescent and activated human CD8+ T cells. Hum Gene Ther (2004) 1.19
Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res (2008) 1.18
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother (2011) 1.18
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood (2006) 1.17